Interestingly, MINDIN expression has been reported to be higher in specimens from patients with more aggressive prostate cancer and worse prognosis, with Gleason score sums of 7–8, and in those with bone metastases [16,17]. This evidence concerns the gene SPON2 and prostate cancer.